Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Doron, Ravid ^a,b,c   Lotan, Dafna ^b,d   Versano, Ziv ^a,d   Benatav, Layla ^a   Franko, Motty ^a   Armoza, Shir ^a,d   Kately, Nadav ^d   Rehavi, Moshe ^d  

^a ACADEMIC COLLEGE OF TEL AVIV YAFFO   (Israel)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; ESCITALOPRAM; HERBACEOUS AGENT; CITALOPRAM; PLANT EXTRACT;

ADOLESCENCE; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CRATAEGUS PINNATIFIDA; DRUG EFFICACY; DRUG MECHANISM; EARLY LIFE STRESS; ELEVATED PLUS MAZE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; LILIUM BROWNIE; LILY; MATERNAL DEPRIVATION; MEDICINAL PLANT; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY; TRITICUM AESTIVUM; ZIZYPHI JUJUBAE; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; BLOOD; COMPLICATION; DRUG EFFECTS; DRUG THERAPY; ETIOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; MOTOR ACTIVITY;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CORTICOSTERONE; MICE, INBRED ICR; MOTOR ACTIVITY; PLANT EXTRACTS; STRESS, PSYCHOLOGICAL;

EID: 84898840556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091455     Document Type: Article

References (56)

1. Thase ME (2006) Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 7: 429-440.
2. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790. (Pubitemid 43090498)
3. De Bellis MD, Van Dillen T (2005) Childhood post-traumatic stress disorder: an overview. Child Adolesc Psychiatr Clin N Am 14: 745-772, ix. (Pubitemid 41323910)
4. Reinhold JA, Mandos LA, Rickels K, Lohoff FW (2011) Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother 12: 2457-2467.
5. Barbui C, Cipriani A (2009) Review: maintenance antidepressants reduce risk of relapse but effect is not as great in recurrent depression. Evid Based Ment Health 12: 79.
6. Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, et al. (2002) The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 14: 143-147. (Pubitemid 36172562)
7. Katzman MA (2009) Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23: 103-120.
8. Linde K, Berner MM, Kriston L (2008) St John's wort for major depression. Cochrane Database Syst Rev: CD000448.
9. Sarris J, Kavanagh DJ (2009) Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med 15: 827-836.
10. Witte S, Loew D, Gaus W (2005) Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 19: 183-188. (Pubitemid 40827638)
11. Panossian A, Gabrielian E, Wagner H (1999) On the mechanism of action of plant adaptogens with particular reference to cucurbitacin R diglucoside. Phytomedicine 6: 147-155. (Pubitemid 129632909)
12. Muller WE, Rolli M, Schafer C, Hafner U (1997) Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30 Suppl 2: 102-107.
13. Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K (1999) Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 19: 59-74. (Pubitemid 29152175)
14. Scheid V, Bensky D, Ellis A, Barolet R (2009) Chinese Herbal Medicine: Formulas and Strategies. CA, USA: Eastland Pr.
15. Doron R, Lotan D, Rak-Rabl A, Raskin-Ramot A, Lavi K, et al. (2012) Anxiolytic effects of a novel herbal treatment in mice models of anxiety. Life Sci 90: 995-1000.
16. Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, et al. (1997) Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary- adrenal responses to stress. Science 277: 1659-1662. (Pubitemid 27446227)
17. Avital A, Richter-Levin G (2005) Exposure to juvenile stress exacerbates the behavioural consequences of exposure to stress in the adult rat. International Journal of Neuropsychopharmacology 8: 163-173. (Pubitemid 40769257)
18. Tsoory M, Cohen H, Richter-Levin G (2007) Juvenile stress induces a predisposition to either anxiety or depressive-like symptoms following stress in adulthood. European Neuropsychopharmacology 17: 245-256. (Pubitemid 46135931)
19. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, et al. (2003) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167: 353-362. (Pubitemid 36754236)
20. Pandey DK, Yadav SK, Mahesh R, Rajkumar R (2009) Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety? Behavioural Brain Research 205: 436-442.
21. Maayan R, Lotan S, Doron R, Shabat-Simon M, Gispan-Herman I, et al. (2006) Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats. Eur Neuropsychopharmacol 16: 329-339. (Pubitemid 43815729)
22. Baker-Herman TL, Fuller DD, Bavis RW, Zabka AG, Golder FJ, et al. (2004) BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nature Neuroscience 7: 48-55. (Pubitemid 38032167)
23. Willner P, Muscat R, Papp M (1992) Chronic Mild Stress-Induced Anhedonia - a Realistic Animal-Model of Depression. Neuroscience and Biobehavioral Reviews 16: 525-534.
24. Ducottet C, Belzung C (2004) Behaviour in the elevated plus-maze predicts coping after subchronic mild stress in mice. Physiology & Behavior 81: 417-426. (Pubitemid 38591530)
25. Carobrez AP, Bertoglio LJ (2005) Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on. Neuroscience and Biobehavioral Reviews 29: 1193-1205. (Pubitemid 41446895)
26. File SE (2001) Factors controlling measures of anxiety and responses to novelty in the mouse. Behavioural Brain Research 125: 151-157.
27. Heim C, Owens MJ, Plotsky PM, Nemeroff CB (1997) The role of early adverse life events in the etiology of depression and posttraumatic stress disorder - Focus on corticotropin-releasing factor. Psychobiology of Posttraumatic Stress Disorder 821: 194-207. (Pubitemid 27343021)
28. Heim C, Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biological Psychiatry 49: 1023-1039. (Pubitemid 32595461)
29. Avitsur R, Hunzeker J, Sheridan JF (2006) Role of early stress in the individual differences in host response to viral infection. Brain Behavior and Immunity 20: 339-348. (Pubitemid 43775787)
30. Romeo RD, Mueller A, Sisti HM, Ogawa S, McEwen BS, et al. (2003) Anxiety and fear behaviors in adult male and female C57BL/6 mice are modulated by maternal separation. Hormones and Behavior 43: 561-567. (Pubitemid 36687844)
31. Millstein RA, Holmes A (2007) Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. Neuroscience and Biobehavioral Reviews 31: 3-17. (Pubitemid 44880075)
32. Kalinichev M, Easterling KW, Plotsky PM, Holtzman SG (2002) Long-lasting changes in stress-induced corticosterone response and anxiety-like behaviors as a consequence of neonatal maternal separation in Long-Evans rats. Pharmacology Biochemistry and Behavior 73: 131-140. (Pubitemid 34667025)
33. Slotten HA, Kalinichev M, Hagan JJ, Marsden CA, Fone KCF (2006) Longlasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: Gender-dependent effects. Brain Research 1097: 123-132. (Pubitemid 44043110)
34. Sanchez MM, Ladd CO, Plotsky PM (2001) Early adverse experience as a developmental risk factor for later psychopathology: Evidence from rodent and primate models. Development and Psychopathology 13: 419-449. (Pubitemid 33406337)
35. Culpepper L (2002) Generalized anxiety disorder in primary care: Emerging issues in management and treatment. Journal of Clinical Psychiatry 63: 35-42.
36. Baldwin DS, Waldman S, Allgulander C (2011) Evidence-based pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 14: 697-710.
37. Dulawa SC, Hollick KA, Gundersen B, Hen R (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29: 1321-1330. (Pubitemid 38780655)
38. Ihne JL, Fitzgerald PJ, Hefner KR, Holmes A (2012) Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice. Neuropharmacology 62: 464-473.
39. Mantella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL, et al. (2008) Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology 33: 773-781.
40. Vreeburg SA, Zitman FG, van Pelt J, DeRijk RH, Verhagen JCM, et al. (2010) Salivary Cortisol Levels in Persons With and Without Different Anxiety Disorders. Psychosomatic Medicine 72: 340-347.
41. Lenze EJ, Mantella RC, Shi PC, Goate AM, Nowotny P, et al. (2011) Elevated Cortisol in Older Adults With Generalized Anxiety Disorder Is Reduced by Treatment: A Placebo-Controlled Evaluation of Escitalopram. American Journal of Geriatric Psychiatry 19: 482-490.
42. Vermetten E, Vythilingam M, Schmahl C, De Kloet C, Southwick SM, et al. (2006) Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder. Psychobiology of Posttraumatic Stress Disorder: A Decade of Progress 1071: 184-202.
43. Buhl ES, Jensen TK, Jessen N, Elfving B, Buhl CS, et al. (2010) Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats. American Journal of Physiology-Endocrinology and Metabolism 298: E920-E929.
44. Schmidt MV, Sterlemann V, Ganea K, Liebl C, Alam S, et al. (2007) Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology 32: 417-429. (Pubitemid 46755998)
45. Middeldorp CM, Slof-Op 't Landt MC, Medland SE, van Beijsterveldt CE, Bartels M, et al. (2010) Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes? Genes Brain Behav 9: 808-816.
46. Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45: 104-114. (Pubitemid 38625738)
47. Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, et al. (2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 180: 95-99. (Pubitemid 40897075)
48. Frielingsdorf H, Bath KG, Soliman F, Difede J, Casey BJ, et al. (2010) Variant brain-derived neurotrophic factor Val66Met endophenotypes: implications for posttraumatic stress disorder. Ann N Y Acad Sci 1208: 150-157.
49. Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, et al. (2004) Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry 55: 708-714. (Pubitemid 38376182)
50. Marco EM, Valero M, de la Serna O, Aisa B, Borcel E, et al. (2012) Maternal deprivation effects on brain plasticity and recognition memory in adolescent male and female rats. Neuropharmacology.
51. Lee TTY, Gorzalka BB (2012) Timing Is Everything: Evidence for a Role of Corticolimbic Endocannabinoids in Modulating Hypothalamic-Pituitary-Adrenal Axis Activity across Developmental Periods. Neuroscience 204: 17-30.
52. Dwivedi Y, Rizavi HS, Pandey GN (2006) Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 139: 1017-1029.
53. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116-1127.
54. Tamaji A, Iwamoto K, Kawamura Y, Takahashi M, Ebe K, et al. (2012) Differential effects of diazepam, tandospirone, and paroxetine on plasma brain-derived neurotrophic factor level under mental stress. Hum Psychopharmacol 27: 329-333.
55. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C (2010) Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiatr Res 44: 808-816.
56. Doron R, Lotan D, Einat N, Yaffe R, Winer A, et al. (2014) A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice. Life Sci 94: 151-157.